WO2021218148A1 - 10-(s)-17-hydrogen-7-dehydro-andrographolidume, industrial chromatography-based preparation method therefor, and use thereof - Google Patents
10-(s)-17-hydrogen-7-dehydro-andrographolidume, industrial chromatography-based preparation method therefor, and use thereof Download PDFInfo
- Publication number
- WO2021218148A1 WO2021218148A1 PCT/CN2020/132794 CN2020132794W WO2021218148A1 WO 2021218148 A1 WO2021218148 A1 WO 2021218148A1 CN 2020132794 W CN2020132794 W CN 2020132794W WO 2021218148 A1 WO2021218148 A1 WO 2021218148A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dehydroandrographolide
- hydro
- preparation
- organic solvent
- crude product
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000004587 chromatography analysis Methods 0.000 title abstract description 4
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 6
- 241000711573 Coronaviridae Species 0.000 claims abstract description 5
- 208000025721 COVID-19 Diseases 0.000 claims abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical class C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 claims description 28
- 239000012043 crude product Substances 0.000 claims description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 21
- 239000003960 organic solvent Substances 0.000 claims description 20
- 238000010828 elution Methods 0.000 claims description 19
- 239000011347 resin Substances 0.000 claims description 18
- 229920005989 resin Polymers 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- 239000003208 petroleum Substances 0.000 claims description 17
- 238000000746 purification Methods 0.000 claims description 17
- 239000003480 eluent Substances 0.000 claims description 14
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 13
- 238000001179 sorption measurement Methods 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 claims description 12
- 239000000741 silica gel Substances 0.000 claims description 12
- 229910002027 silica gel Inorganic materials 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 238000012856 packing Methods 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 238000001953 recrystallisation Methods 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical group O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 26
- 150000001875 compounds Chemical class 0.000 abstract description 13
- 239000002158 endotoxin Substances 0.000 abstract description 10
- 229920006008 lipopolysaccharide Polymers 0.000 abstract description 10
- 210000002540 macrophage Anatomy 0.000 abstract description 7
- 238000012404 In vitro experiment Methods 0.000 abstract description 2
- 229940123134 Nitric oxide inhibitor Drugs 0.000 abstract description 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 239000003517 fume Substances 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000000825 ultraviolet detection Methods 0.000 description 4
- 244000118350 Andrographis paniculata Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 0 CC(C)([C@]1[C@@](*)(CC2)[C@](CC=C([C@@](CO3)O)*3=O)C(*)=CC1)[C@]2O Chemical compound CC(C)([C@]1[C@@](*)(CC2)[C@](CC=C([C@@](CO3)O)*3=O)C(*)=CC1)[C@]2O 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000033687 granuloma formation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- -1 small molecule compounds Chemical class 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide, a preparation method thereof, and use of the andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide for preparing drugs for treating inflammation.
- Andrographis paniculata (Burm.F.)Nees is extracted from the whole plant of Andrographis paniculata (Burm.F.)Nees. It has antibacterial, anti-inflammatory, detoxification and other effects. It is an important active natural product. Andrographolide and its derivatives have been made into a variety of dosage forms (tablets, dripping pills, capsules, etc.) and are widely used in clinical practice, such as Xiyanping injection, Lianbizhi injection, Yanhuning injection, and Andrographis paniculata Ester tablets, etc. have shown good clinical effects of clearing away heat, detoxifying, anti-bacterial and anti-inflammatory. Luvone et al.
- nitric oxide is related to the occurrence of acute and chronic inflammation [Luvone T, Carnuccio R, Di RM. Modulation of granuloma formation endogenous nitric oxide [J]. Eur J Pharmacol, 1994, 265(1/2) ):89-92.]. Andrographolide can significantly down-regulate the expression of inflammatory factors NO, tumor necrosis factor- ⁇ (TNF- ⁇ ) and interleukin (IL)-6 in mouse macrophages RAW264.7 induced by lipopolysaccharide, thereby inhibiting the inflammatory response.
- TNF- ⁇ tumor necrosis factor- ⁇
- IL-6 interleukin-6
- Xiyanping injection which is widely used clinically, has the functions of clearing away heat, detoxifying, antibacterial and anti-inflammatory, but the active ingredient of Xiyanping injection is the sulfonated product of andrographolide, which is not a single structure.
- the use of single-structure small molecule compounds to further clarify the mechanism is of great significance to the study of its pharmacodynamics and toxicology; although andrographolides have achieved some research results, there is still nothing new for many diseases, especially in the field of anti-inflammatory
- the particularly effective andrographolide derivatives or analogues are used clinically. Therefore, the development of new andrographolide derivative monomer drugs with anti-inflammatory activity has important social significance.
- the present invention provides a new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide and its preparation method and application.
- the first aspect of the present invention provides a new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide formula (I),
- the second aspect of the present invention provides a method for preparing a new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide,
- Macroporous adsorption resin column purification Dissolve andrographolide total sulfonate in water, load the sample on the macroporous adsorption resin column, use a mixed solvent of organic solvent and water for elution, and combine to contain 10-(S)-17- The eluent of hydrogen-7-dehydroandrographolide was concentrated to obtain crude product 1;
- the macroporous adsorption resin is a styrene-type macroporous adsorption resin, more preferably, the styrene-type macroporous adsorption resin model HPD-100S, D101S or LX-1180.
- the organic solvent is an alcohol solvent, such as methanol or ethanol.
- the organic solvent and water mixed solvent are 0%-60% methanol aqueous solution (preferably 35%-55% methanol aqueous solution) or 0%-60% ethanol aqueous solution (preferably 30%) by volume. % ⁇ 50% ethanol aqueous solution).
- the elution is a gradient elution, such as: eluting with a volume ratio of 35%, 45%, and 55% methanol-water solution in sequence, or using a volume ratio of 30%, 40% in sequence. , 50% ethanol-water solution for elution.
- a gradient elution such as: eluting with a volume ratio of 35%, 45%, and 55% methanol-water solution in sequence, or using a volume ratio of 30%, 40% in sequence. , 50% ethanol-water solution for elution.
- the concentration temperature is 40-50°C.
- A is one of petroleum ether or cyclohexane
- B is one of ethyl acetate, dichloromethane, chloroform or acetone ;
- the mixed organic solvent (A/B) is a petroleum ether/acetone solution
- a petroleum ether/acetone solution with a volume ratio of 5:1 to 4:1 is used for dissolution; and/or a petroleum ether/acetone solution with a volume ratio of 5:1 to 1::1 is used for elution.
- the elution is a gradient elution, for example, a petroleum ether-acetone solution with a volume ratio of 5:1, 3:1, 2:1, and 1:1 is used for elution in sequence.
- a gradient elution for example, a petroleum ether-acetone solution with a volume ratio of 5:1, 3:1, 2:1, and 1:1 is used for elution in sequence.
- the concentration temperature is 40-50°C.
- the packing of the HPLC chromatographic column is a reversed-phase C18 packing, more preferably XAqua, ODS-A or ODS-AQ.
- the detection wavelength of the ultraviolet on-line detector is 150-300 nm, more preferably 225 nm.
- the organic solvent is ethyl acetate.
- the number of recrystallization is greater than or equal to 2 times.
- the drying method is vacuum drying.
- the drying temperature is 40-50°C.
- the third aspect of the present invention provides a new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide as a pharmaceutical active ingredient of the drug formulation, including but not limited to injections, tablets, Capsules, dispersible tablets.
- the fourth aspect of the present invention provides the use of the above-mentioned new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide or the above-mentioned pharmaceutical preparation in the preparation of a medicine for the treatment of inflammatory diseases.
- the inflammatory disease is preferably pneumonia, and the pneumonia is preferably new coronavirus pneumonia (COVID-19).
- the present invention provides a new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide compound of formula (I).
- LPS lipopolysaccharide
- NO nitric oxide
- RAW264.7 macrophages have a significant inhibitory effect. Therefore, the compound can be used as an inhibitor of nitric oxide and made into an anti-inflammatory drug for the treatment of inflammatory diseases. Further, it can be used for treatment Pneumonia, such as the new coronavirus pneumonia (COVID-19).
- the preparation method of 10-(S)-17-hydro-7-dehydroandrographolide provided by the present invention has convenient operation and high yield.
- Industrial chromatography technology can be used to prepare the compound with high purity in large quantities, which is suitable for large-scale production. .
- Fig. 1 10-(S)-17-hydro-7-dehydroandrographolide hydrogen nuclear magnetic resonance spectrum of Example 2;
- FIG. 1 HPLC detection diagram of 10-(S)-17-hydro-7-dehydroandrographolide in Example 2;
- FIG. 4 Example 2 of 10-(S)-17-hydro-7-dehydroandrographolide anti-inflammatory activity test.
- Purification by macroporous adsorption resin column Take 200.00g of andrographolide total sulfonate, add appropriate amount of purified water to dissolve it, load the sample on D101S macroporous adsorption resin column, and use volume ratio 30%, 40%, 50% ethanol-water solution in turn Perform elution, combine the eluted fractions containing 10-(S)-17-hydro-7-dehydroandrographolide, and concentrate under reduced pressure at 40°C to obtain crude product 1;
- the proton nuclear magnetic resonance spectrum 1 H-NMR (400MH Z ) and the carbon nuclear magnetic resonance spectrum 13 C-NMR (100MH Z ) are shown in Figure 1 and Figure 2, and the data is shown in Table 1.
- Example 2 The compound obtained in Example 2 was applied to lipopolysaccharide (LPS)-induced RAW264.7 mouse macrophages, and the level of NO in the culture supernatant was detected by the Griess reagent colorimetric method. The ability of the tested drug to inhibit the release of NO was used as Screen indicators to evaluate the anti-inflammatory activity of the compound.
- LPS lipopolysaccharide
- the monomer compound was dissolved in DMSO to prepare a solution of 1.564, 3.125, 6.250, 12.50, 25.00 ⁇ g/ml.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Provided is a new compound 10-(S)-17-hydrogen-7-dehydro-andrographolidume. An in vitro experiment shows that the compound has a significant inhibition effect on the generation of nitric oxide (NO) in RAW264.7 macrophage induced by lipopolysaccharide (LPS). Therefore, the compound may be used as a nitric oxide inhibitor, and is prepared to an anti-inflammatory drug for treating novel coronavirus pneumonia (COVID-19). Further provided is a preparation method for 10-(S)-17-hydrogen-7-dehydro-andrographolidume; the method is easy to operate and high in yield, can be used for preparing the compound having high purity by using an industrial chromatography technology, and is suitable for large-scale production.
Description
本申请要求申请日为2020/4/30的中国专利申请202010362402.1的优先权。本申请引用上述中国专利申请的全文。This application claims the priority of the Chinese patent application 202010362402.1 whose filing date is 2020/4/30. This application quotes the full text of the aforementioned Chinese patent application.
本发明涉及穿心莲内酯衍生物10-(S)-17-氢-7-去氢穿心莲内酯及其制备方法和其用于制备治疗炎症药物的用途。The present invention relates to andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide, a preparation method thereof, and use of the andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide for preparing drugs for treating inflammation.
穿心莲内酯是从爵床科植物穿心莲[Andrographis paniculata(Burm.F.)Nees]全草中提取的半日花烷型二萜类化合物,具有抗菌消炎,解毒等功效,是一种重要的活性天然产物。穿心莲内酯及其衍生物已经被制成多种剂型(片剂、滴丸、胶囊等)广泛应用于临床,如喜炎平注射液、莲必治注射液、炎琥宁注射液、穿心莲内酯片等在临床上均表现出良好的清热解毒、抗菌消炎功效。Luvone等认为,一氧化氮(NO)与急慢性炎症的发生均相关[Luvone T,Carnuccio R,Di RM.Modulation of granuloma formation endogenous nitric oxide[J].Eur J Pharmacol,1994,265(1/2):89-92.]。穿心莲内酯能够明显下调脂多糖诱导的小鼠巨噬细胞RAW264.7中炎症因子NO、肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-6的表达,从而抑制炎症反应。Andrographis paniculata (Burm.F.)Nees is extracted from the whole plant of Andrographis paniculata (Burm.F.)Nees. It has antibacterial, anti-inflammatory, detoxification and other effects. It is an important active natural product. Andrographolide and its derivatives have been made into a variety of dosage forms (tablets, dripping pills, capsules, etc.) and are widely used in clinical practice, such as Xiyanping injection, Lianbizhi injection, Yanhuning injection, and Andrographis paniculata Ester tablets, etc. have shown good clinical effects of clearing away heat, detoxifying, anti-bacterial and anti-inflammatory. Luvone et al. believe that nitric oxide (NO) is related to the occurrence of acute and chronic inflammation [Luvone T, Carnuccio R, Di RM. Modulation of granuloma formation endogenous nitric oxide [J]. Eur J Pharmacol, 1994, 265(1/2) ):89-92.]. Andrographolide can significantly down-regulate the expression of inflammatory factors NO, tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 in mouse macrophages RAW264.7 induced by lipopolysaccharide, thereby inhibiting the inflammatory response.
目前临床上广泛使用的喜炎平注射液,具有清热解毒、抗菌消炎等功能,但是喜炎平注射液的活性成分为穿心莲内酯的磺化产物,并非单一结构。采用单一结构的小分子化合物以进一步明确机理,对其药效及其毒理学研究具有重要意义;尽管穿心莲内酯类化合物已取得一些研究成果,但是对于多种疾病,尤其抗炎领域仍然没有新的特别有效的穿心莲内酯衍生物或类似物用于临床。因此,开发新的具有抗炎活性的穿心莲内酯衍生物单体药物具有重要的社会意义。At present, Xiyanping injection, which is widely used clinically, has the functions of clearing away heat, detoxifying, antibacterial and anti-inflammatory, but the active ingredient of Xiyanping injection is the sulfonated product of andrographolide, which is not a single structure. The use of single-structure small molecule compounds to further clarify the mechanism is of great significance to the study of its pharmacodynamics and toxicology; although andrographolides have achieved some research results, there is still nothing new for many diseases, especially in the field of anti-inflammatory The particularly effective andrographolide derivatives or analogues are used clinically. Therefore, the development of new andrographolide derivative monomer drugs with anti-inflammatory activity has important social significance.
发明内容Summary of the invention
为了克服现有技术的不足,本发明提供了一种新的穿心莲内酯衍生物10-(S)-17-氢-7-去氢穿心莲内酯及其制备方法和应用。In order to overcome the shortcomings of the prior art, the present invention provides a new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide and its preparation method and application.
本发明第一方面,提供一种新穿心莲内酯衍生物10-(S)-17-氢-7-去氢穿心莲内酯式(Ι),The first aspect of the present invention provides a new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide formula (I),
本发明第二方面,提供一种新穿心莲内酯衍生物10-(S)-17-氢-7-去氢穿心莲内酯的制备方法,The second aspect of the present invention provides a method for preparing a new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide,
包括以下步骤:It includes the following steps:
(1)大孔吸附树脂柱纯化:将穿心莲内酯总磺化物用水溶解,上样于大孔吸附树脂柱,采用有机溶剂和水混合溶剂进行洗脱,合并含有10-(S)-17-氢-7-去氢穿心莲内酯的洗脱液,浓缩,得粗品1;(1) Macroporous adsorption resin column purification: Dissolve andrographolide total sulfonate in water, load the sample on the macroporous adsorption resin column, use a mixed solvent of organic solvent and water for elution, and combine to contain 10-(S)-17- The eluent of hydrogen-7-dehydroandrographolide was concentrated to obtain crude product 1;
(2)硅胶柱纯化:将粗品1用混合有机溶剂(A/B)溶解,上样于硅胶柱进行纯化,用混合有机溶剂(A/B)洗脱,用紫外在线检测器检测分离情况,根据出峰时间及色谱峰高度,确定洗脱液收集起止时间,收集洗脱液进行HPLC检测,根据检测结果合并含有10-(S)-17-氢-7-去氢穿心莲内酯的洗脱液,浓缩,得粗品2;(2) Silica gel column purification: dissolve the crude product 1 in a mixed organic solvent (A/B), load the sample on a silica gel column for purification, elution with a mixed organic solvent (A/B), and detect the separation with a UV on-line detector. According to the peak time and chromatographic peak height, determine the start and end time of eluent collection, collect the eluent for HPLC detection, and combine the elution containing 10-(S)-17-hydro-7-dehydroandrographolide according to the test results Liquid, concentrate, get crude product 2;
(3)重结晶:将粗品2用有机溶剂溶解,挥发部分有机溶剂,析出固体,过滤,干 燥。(3) Recrystallization: Dissolve the crude product 2 in an organic solvent, evaporate part of the organic solvent, and precipitate a solid, filter and dry.
优选的,所述步骤(1)中,大孔吸附树脂为苯乙烯型大孔吸附树脂,更优选的,苯乙烯型大孔吸附树脂型号HPD-100S、D101S或LX-1180。Preferably, in the step (1), the macroporous adsorption resin is a styrene-type macroporous adsorption resin, more preferably, the styrene-type macroporous adsorption resin model HPD-100S, D101S or LX-1180.
优选的,所述步骤(1)中,有机溶剂为醇类溶剂,如甲醇或乙醇。Preferably, in the step (1), the organic solvent is an alcohol solvent, such as methanol or ethanol.
优选的,所述步骤(1)中,有机溶剂和水混合溶剂为体积比0%~60%甲醇水溶液(优选35%~55%甲醇水溶液)或体积比0%~60%乙醇水溶液(优选30%~50%乙醇水溶液)。Preferably, in the step (1), the organic solvent and water mixed solvent are 0%-60% methanol aqueous solution (preferably 35%-55% methanol aqueous solution) or 0%-60% ethanol aqueous solution (preferably 30%) by volume. %~50% ethanol aqueous solution).
优选的,所述步骤(1)中,洗脱为梯度洗脱,如:依次用体积比35%、45%、55%甲醇-水溶液进行洗脱,或,依次用体积比30%、40%、50%乙醇-水溶液进行洗脱。Preferably, in the step (1), the elution is a gradient elution, such as: eluting with a volume ratio of 35%, 45%, and 55% methanol-water solution in sequence, or using a volume ratio of 30%, 40% in sequence. , 50% ethanol-water solution for elution.
优选的,所述步骤(1)中,浓缩温度为40~50℃。Preferably, in the step (1), the concentration temperature is 40-50°C.
优选的,所述步骤(2)中,混合有机溶剂(A/B)中A为石油醚或环己烷中的一种,B为乙酸乙酯、二氯甲烷、氯仿或丙酮中的一种;Preferably, in the step (2), in the mixed organic solvent (A/B), A is one of petroleum ether or cyclohexane, and B is one of ethyl acetate, dichloromethane, chloroform or acetone ;
更优选的,混合有机溶剂(A/B)为石油醚/丙酮溶液;More preferably, the mixed organic solvent (A/B) is a petroleum ether/acetone solution;
进一步优选的,溶解时采用体积比5:1~4:1的石油醚/丙酮溶液;和/或,洗脱时采用溶剂为体积比5:1~1:1的石油醚/丙酮溶液。More preferably, a petroleum ether/acetone solution with a volume ratio of 5:1 to 4:1 is used for dissolution; and/or a petroleum ether/acetone solution with a volume ratio of 5:1 to 1::1 is used for elution.
优选的,所述步骤(2)中,洗脱为梯度洗脱,如:依次用体积比为5:1、3:1、2:1、1:1的石油醚-丙酮溶液进行洗脱。Preferably, in the step (2), the elution is a gradient elution, for example, a petroleum ether-acetone solution with a volume ratio of 5:1, 3:1, 2:1, and 1:1 is used for elution in sequence.
优选的,所述步骤(2)中,浓缩温度为40~50℃。Preferably, in the step (2), the concentration temperature is 40-50°C.
优选的,所述步骤(2)中,HPLC色谱柱的填料为反相C18填料,更优选为XAqua、ODS-A或ODS-AQ。Preferably, in the step (2), the packing of the HPLC chromatographic column is a reversed-phase C18 packing, more preferably XAqua, ODS-A or ODS-AQ.
优选的,所述步骤(2)中,紫外在线检测器的检测波长为150~300nm,更优选为225nm。Preferably, in the step (2), the detection wavelength of the ultraviolet on-line detector is 150-300 nm, more preferably 225 nm.
优选的,所述步骤(3)中,有机溶剂为乙酸乙酯。Preferably, in the step (3), the organic solvent is ethyl acetate.
优选的,所述步骤(3)中,重结晶次数大于或等于2次。Preferably, in the step (3), the number of recrystallization is greater than or equal to 2 times.
优选的,所述步骤(3)中,干燥方法为减压干燥。Preferably, in the step (3), the drying method is vacuum drying.
优选的,所述步骤(3)中,干燥温度40~50℃。Preferably, in the step (3), the drying temperature is 40-50°C.
本发明的第三方面,提供一种新穿心莲内酯衍生物10-(S)-17-氢-7-去氢穿心莲内酯作为药物活性成分的药物制剂,包括但不限于注射剂、片剂、胶囊、分散片。The third aspect of the present invention provides a new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide as a pharmaceutical active ingredient of the drug formulation, including but not limited to injections, tablets, Capsules, dispersible tablets.
本发明的第四方面,提供上述的新穿心莲内酯衍生物10-(S)-17-氢-7-去氢穿心莲内酯或上述的药物制剂在制备治疗炎症疾病药物中的用途,所述炎症疾病优选肺炎,所述肺炎优选新型冠状病毒肺炎(COVID-19)。The fourth aspect of the present invention provides the use of the above-mentioned new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide or the above-mentioned pharmaceutical preparation in the preparation of a medicine for the treatment of inflammatory diseases. The inflammatory disease is preferably pneumonia, and the pneumonia is preferably new coronavirus pneumonia (COVID-19).
本发明的有益技术效果The beneficial technical effects of the present invention
1.本发明提供一种新穿心莲内酯衍生物10-(S)-17-氢-7-去氢穿心莲内酯式(Ι)化合物,经体外实验表明该化合物对脂多糖(LPS)诱导的RAW264.7巨噬细胞中一氧化氮(NO)的产生具有显著的抑制作用,因此该化合物可作为一氧化氮抑制剂,制成抗炎药物,用于治疗炎症疾病,进一步的,可用于治疗肺炎,如新型冠状病毒肺炎(COVID-19)。1. The present invention provides a new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide compound of formula (I). In vitro experiments show that the compound is induced by lipopolysaccharide (LPS) The production of nitric oxide (NO) in RAW264.7 macrophages has a significant inhibitory effect. Therefore, the compound can be used as an inhibitor of nitric oxide and made into an anti-inflammatory drug for the treatment of inflammatory diseases. Further, it can be used for treatment Pneumonia, such as the new coronavirus pneumonia (COVID-19).
2.本发明提供的10-(S)-17-氢-7-去氢穿心莲内酯制备方法,操作方便,收率高,可采用工业色谱技术大量制备高纯度该化合物,适用于大规模生产。2. The preparation method of 10-(S)-17-hydro-7-dehydroandrographolide provided by the present invention has convenient operation and high yield. Industrial chromatography technology can be used to prepare the compound with high purity in large quantities, which is suitable for large-scale production. .
图1:实施例2的10-(S)-17-氢-7-去氢穿心莲内酯核磁共振氢谱图;Fig. 1: 10-(S)-17-hydro-7-dehydroandrographolide hydrogen nuclear magnetic resonance spectrum of Example 2;
图2:实施例2的10-(S)-17-氢-7-去氢穿心莲内酯核磁共振碳谱图;Figure 2: 10-(S)-17-hydro-7-dehydroandrographolide carbon NMR spectrum of Example 2;
图3:实施例2的10-(S)-17-氢-7-去氢穿心莲内酯HPLC检测图;Figure 3: HPLC detection diagram of 10-(S)-17-hydro-7-dehydroandrographolide in Example 2;
图4:实施例2的10-(S)-17-氢-7-去氢穿心莲内酯抗炎活性测试。Figure 4: Example 2 of 10-(S)-17-hydro-7-dehydroandrographolide anti-inflammatory activity test.
在如下的实施例中所指的10-(S)-17-氢-7-去氢穿心莲内酯的化学结构式(结构中的阿拉伯数字是化学结构中碳原子的标位):The chemical structural formula of 10-(S)-17-hydro-7-dehydroandrographolide referred to in the following examples (the Arabic number in the structure is the index of the carbon atom in the chemical structure):
实施例1:穿心莲内酯总磺化物的制备Example 1: Preparation of andrographolide total sulfonate
取无水乙醇50L,置反应釜中,缓慢加入20L浓硫酸,搅拌均匀后,加入50.00kg穿心莲内酯,搅拌,常温放置72小时。控制温度加入50L 95%乙醇,搅拌,加入50%氢氧化钠溶液调pH至7.0,加入乙醇至含醇量85%,静置24小时,过滤,滤液回收乙醇,浓缩成稠膏,真空干燥即得穿心莲内酯总磺化物。Take 50L of absolute ethanol, place it in the reaction kettle, slowly add 20L of concentrated sulfuric acid, and after stirring evenly, add 50.00kg of andrographolide, stir, and place at room temperature for 72 hours. Control the temperature by adding 50L 95% ethanol, stir, add 50% sodium hydroxide solution to adjust the pH to 7.0, add ethanol to 85% alcohol content, let stand for 24 hours, filter, the filtrate recovers ethanol, concentrates into a thick paste, vacuum dried Get andrographolide total sulfonates.
实施例2-5:10-(S)-17-氢-7-去氢穿心莲内酯的制备Example 2-5: Preparation of 10-(S)-17-hydro-7-dehydroandrographolide
实施例2Example 2
(1)大孔吸附树脂柱纯化:取穿心莲内酯总磺化物200.00g,加适量纯化水溶解后上样D101S大孔吸附树脂柱,依次用体积比30%、40%、50%乙醇-水溶液进行洗脱,合并含有10-(S)-17-氢-7-去氢穿心莲内酯的洗脱流份,40℃减压浓缩干,得粗品1;(1) Purification by macroporous adsorption resin column: Take 200.00g of andrographolide total sulfonate, add appropriate amount of purified water to dissolve it, load the sample on D101S macroporous adsorption resin column, and use volume ratio 30%, 40%, 50% ethanol-water solution in turn Perform elution, combine the eluted fractions containing 10-(S)-17-hydro-7-dehydroandrographolide, and concentrate under reduced pressure at 40°C to obtain crude product 1;
(2)硅胶柱纯化:将粗品1用适量体积比5:1石油醚-丙酮溶解后上样硅胶柱,依次用体积比为5:1、3:1、2:1、1:1的石油醚-丙酮溶液进行洗脱,用紫外在线检测器检测分离情况,根据出峰时间及色谱峰高度,确定洗脱液收集起止时间,收集洗脱液进行HPLC检测,HPLC色谱柱填料为XAqua(反向C18填料),紫外检测波长为225nm。根据检测结果合并含有10-(S)-17-氢-7-去氢穿心莲内酯的洗脱流份,40℃减压浓缩干,得粗品2;(2) Silica gel column purification: dissolve crude product 1 with an appropriate volume ratio of 5:1 petroleum ether-acetone, then load the sample on a silica gel column, and use petroleum with volume ratios of 5:1, 3:1, 2:1, and 1:1 in turn Ether-acetone solution was used for elution, and the separation situation was detected with an ultraviolet online detector. According to the peak time and the height of the chromatographic peak, the start and end time of the eluent collection was determined, and the eluent was collected for HPLC detection. The HPLC column packing was XAqua (reverse Filling to C18), UV detection wavelength is 225nm. According to the test results, the eluted fractions containing 10-(S)-17-hydro-7-dehydroandrographolide were combined, and concentrated under reduced pressure at 40°C to obtain crude product 2;
(3)重结晶:将粗品2加入适量乙酸乙酯溶解,放置通风橱挥发掉部分溶剂至大量固体析出,过滤,固体继续加入适量乙酸乙酯溶解,放置通风橱挥发掉部分溶剂至大量固体析出,过滤,固体40℃减压干燥,得10-(S)-17-氢-7-去氢穿心莲内酯4.53g,纯度96.33%。(3) Recrystallization: Add appropriate amount of ethyl acetate to dissolve the crude product 2, place it in a fume hood to volatilize part of the solvent until a large amount of solids precipitate, filter, continue to add an appropriate amount of ethyl acetate to dissolve the solid, place a fume hood to volatilize part of the solvent to a large amount of solids precipitate , Filtered, and the solid was dried under reduced pressure at 40°C to obtain 4.53 g of 10-(S)-17-hydro-7-dehydroandrographolide with a purity of 96.33%.
经NMR、ESI-MS等现代光谱技术鉴定了化合物10-(S)-17-氢-7-去氢穿心莲内酯的化学结构,并通过X-射线单晶衍射确定了该化合物绝对构型,其理化性质如下:The chemical structure of compound 10-(S)-17-hydro-7-dehydroandrographolide was identified by modern spectroscopy techniques such as NMR and ESI-MS, and the absolute configuration of the compound was determined by X-ray single crystal diffraction. Its physical and chemical properties are as follows:
白色粉末,分子式为:C
20H
30O
5;
White powder, molecular formula: C 20 H 30 O 5 ;
高分辨质谱HRESIMS m/z 349.2021[M–H]
–(cald.for.C
20H
29O
5,349.2015)。核磁共振氢谱
1H-NMR(400MH
Z)及核磁共振碳谱
13C-NMR(100MH
Z),见图1和图2,数据见表1。
High resolution mass spectrometry HRESIMS m/z 349.2021[M–H] – (cald.for.C 20 H 29 O 5 ,349.2015). The proton nuclear magnetic resonance spectrum 1 H-NMR (400MH Z ) and the carbon nuclear magnetic resonance spectrum 13 C-NMR (100MH Z ) are shown in Figure 1 and Figure 2, and the data is shown in Table 1.
表1 10-(S)-17-氢-7-去氢穿心莲内酯的氢谱和碳谱数据(400/100MHz,DMSO)Table 1 Hydrogen spectrum and carbon spectrum data of 10-(S)-17-hydro-7-dehydroandrographolide (400/100MHz, DMSO)
实施例3Example 3
(1)大孔吸附树脂柱纯化:取穿心莲内酯总磺化物200.08g,加适量纯化水溶解后上样HPD-100S大孔树脂柱,依次用体积比35%、45%、55%甲醇-水溶液进行洗脱,合并含有10-(S)-17-氢-7-去氢穿心莲内酯的洗脱流份,50℃减压浓缩干,得粗品1;(1) Purification by macroporous adsorption resin column: Take 200.08g of andrographolide total sulfonate, add appropriate amount of purified water to dissolve it, and load the HPD-100S macroporous resin column with volume ratio of 35%, 45%, and 55% methanol in sequence. The aqueous solution was eluted, and the eluted fractions containing 10-(S)-17-hydro-7-dehydroandrographolide were combined, and concentrated under reduced pressure at 50°C to obtain crude product 1;
(2)硅胶柱纯化:将粗品1用适量体积比5:1石油醚/丙酮混合溶剂溶解后上样于硅胶柱进行纯化,依次用体积比为5:1、3:1、2:1、1:1石油醚-丙酮溶液进行洗脱,用紫外在线检测器检测分离情况,根据出峰时间及色谱峰高度,确定洗脱液收集起止时间,收集洗脱液进行HPLC检测,HPLC色谱柱填料为ODS-A(反向C18填料),紫外检测波长为225nm。根据检测结果合并含有10-(S)-17-氢-7-去氢穿心莲内酯的洗脱流份,50℃减压浓缩干,得粗品2;(2) Silica gel column purification: Dissolve the crude product 1 in a 5:1 petroleum ether/acetone mixed solvent with a volume ratio of 5:1, and then load the sample on a silica gel column for purification, using volume ratios of 5:1, 3:1, 2:1 in turn 1:1 petroleum ether-acetone solution was used for elution, and the separation situation was detected by UV on-line detector. According to the peak time and chromatographic peak height, determine the start and end time of eluent collection, collect eluent for HPLC detection, HPLC column packing It is ODS-A (reverse C18 filler), and the UV detection wavelength is 225nm. According to the test results, the eluted fractions containing 10-(S)-17-hydro-7-dehydroandrographolide were combined, and concentrated under reduced pressure at 50°C to obtain crude product 2;
(3)重结晶:将粗品2加入适量乙酸乙酯溶解,放置通风橱挥发掉部分溶剂至大量固体析出,过滤,固体继续加入适量乙酸乙酯溶解,放置通风橱挥发掉部分溶剂至大量固体析出,过滤,固体50℃减压干燥,得10-(S)-17-氢-7-去氢穿心莲内酯4.39g,纯度96.54%。(3) Recrystallization: Add appropriate amount of ethyl acetate to dissolve the crude product 2, place it in a fume hood to volatilize part of the solvent until a large amount of solids precipitate, filter, continue to add an appropriate amount of ethyl acetate to dissolve the solid, place a fume hood to volatilize part of the solvent to a large amount of solids precipitate , Filtered, and the solid was dried under reduced pressure at 50°C to obtain 4.39 g of 10-(S)-17-hydro-7-dehydroandrographolide with a purity of 96.54%.
实施例4Example 4
(1)大孔吸附树脂柱纯化:取穿心莲内酯总磺化物200.15g,加适量纯化水溶解后上样LX-1180大孔树吸附脂柱,依次用体积比30%、40%、50%乙醇-水溶液进行洗脱,合并含有10-(S)-17-氢-7-去氢穿心莲内酯的洗脱流份,40℃减压浓缩干,得粗品1;(1) Purification by macroporous resin column: Take 200.15g of andrographolide total sulfonate, add appropriate amount of purified water to dissolve it, and load LX-1180 macroporous resin column with 30%, 40%, 50% volume ratio in turn Ethanol-aqueous solution was used for elution, and the eluted fractions containing 10-(S)-17-hydro-7-dehydroandrographolide were combined and concentrated under reduced pressure at 40°C to obtain crude product 1;
(2)硅胶柱纯化:将粗品1用适量体积比4:1石油醚/丙酮溶液溶解后上样于硅胶柱进行纯化,依次用体积比为5:1、3:1、2:1、1:1的石油醚-丙酮溶液进行洗脱,用紫外在线检测器检测分离情况,根据出峰时间及色谱峰高度,确定洗脱液收集起止时间,收集洗脱液进行HPLC检测,HPLC色谱柱填料为ODS-AQ(反向C18填料),紫外检测波长为225nm。根据检测结果合并含有10-(S)-17-氢-7-去氢穿心莲内酯的洗脱流份,40℃减压浓缩干,得粗品2;(2) Silica gel column purification: Dissolve the crude product 1 with an appropriate volume ratio 4:1 petroleum ether/acetone solution and load the sample on a silica gel column for purification, using volume ratios of 5:1, 3:1, 2:1, 1 :1 petroleum ether-acetone solution for elution, use UV online detector to detect the separation, determine the start and end time of eluent collection according to the peak time and chromatographic peak height, collect eluent for HPLC detection, HPLC column packing It is ODS-AQ (reverse C18 filler), and the UV detection wavelength is 225nm. According to the test results, the eluted fractions containing 10-(S)-17-hydro-7-dehydroandrographolide were combined, and concentrated under reduced pressure at 40°C to obtain crude product 2;
(3)重结晶:将粗品2加入适量乙酸乙酯溶解,放置通风橱挥发掉部分溶剂至大量固体析出,过滤,固体继续加入适量乙酸乙酯溶解,放置通风橱挥发掉部分溶剂至大量固体析出,过滤,固体50℃减压干燥,得10-(S)-17-氢-7-去氢穿心莲内酯4.72g,纯度96.19%。(3) Recrystallization: Add appropriate amount of ethyl acetate to dissolve the crude product 2, place it in a fume hood to volatilize part of the solvent until a large amount of solids precipitate, filter, continue to add an appropriate amount of ethyl acetate to dissolve the solid, place a fume hood to volatilize part of the solvent to a large amount of solids precipitate , Filtered, and the solid was dried under reduced pressure at 50°C to obtain 4.72 g of 10-(S)-17-hydro-7-dehydroandrographolide with a purity of 96.19%.
实施例5Example 5
(1)大孔吸附树脂柱纯化:取穿心莲内酯总磺化物20.15kg,加适量纯化水溶解后 上样HPD-100S大孔树脂柱,依次用体积比35%、45%、55%甲醇-水溶液进行洗脱,合并含有10-(S)-17-氢-7-去氢穿心莲内酯的洗脱流份,50℃减压浓缩干,得粗品1;(1) Purification by macroporous adsorption resin column: Take 20.15 kg of andrographolide total sulfonate, add appropriate amount of purified water to dissolve it, and load the HPD-100S macroporous resin column with volume ratio of 35%, 45%, and 55% methanol in sequence. The aqueous solution was eluted, and the eluted fractions containing 10-(S)-17-hydro-7-dehydroandrographolide were combined, and concentrated under reduced pressure at 50°C to obtain crude product 1;
(2)工业色谱级硅胶柱纯化:将粗品1用适量体积比5:1石油醚/丙酮混合溶剂溶解后上样于工业色谱系统纯化(DAC-HB300动态轴向压缩柱,硅胶填料),依次用体积比为5:1、3:1、2:1、1:1石油醚-丙酮溶液进行洗脱,用紫外在线检测器检测分离情况,根据出峰时间及色谱峰高度,确定洗脱液收集起止时间,收集洗脱液进行HPLC检测,HPLC色谱柱填料为ODS-A(反向C18填料),紫外检测波长为225nm。根据检测结果合并含有10-(S)-17-氢-7-去氢穿心莲内酯的洗脱流份,40℃减压浓缩干,得粗品2;(2) Purification by industrial chromatography-grade silica gel column: Dissolve crude product 1 in a 5:1 petroleum ether/acetone mixed solvent with an appropriate volume ratio and load the sample on an industrial chromatography system for purification (DAC-HB300 dynamic axial compression column, silica gel packing), and then Elute with a volume ratio of 5:1, 3:1, 2:1, 1:1 petroleum ether-acetone solution, use an ultraviolet online detector to detect the separation, and determine the eluent according to the peak time and chromatographic peak height Collect the start and end time, collect the eluent for HPLC detection, the HPLC column packing is ODS-A (reverse C18 packing), and the ultraviolet detection wavelength is 225nm. According to the test results, the eluted fractions containing 10-(S)-17-hydro-7-dehydroandrographolide were combined, and concentrated under reduced pressure at 40°C to obtain crude product 2;
(3)重结晶:将粗品2加入适量乙酸乙酯溶解,放置通风橱挥发掉部分溶剂至大量固体析出,过滤,固体继续加入适量乙酸乙酯溶解,放置通风橱挥发掉部分溶剂至大量固体析出,过滤,固体40℃减压干燥,得10-(S)-17-氢-7-去氢穿心莲内酯415.28g,纯度96.08%。(3) Recrystallization: Add appropriate amount of ethyl acetate to dissolve the crude product 2, place it in a fume hood to volatilize part of the solvent until a large amount of solids precipitate, filter, continue to add an appropriate amount of ethyl acetate to dissolve the solid, place a fume hood to volatilize part of the solvent to a large amount of solids precipitate , Filtered, and the solid was dried under reduced pressure at 40°C to obtain 415.28 g of 10-(S)-17-hydro-7-dehydroandrographolide with a purity of 96.08%.
实施例6:10-(S)-17-氢-7-去氢穿心莲内酯抗炎活性测试Example 6: 10-(S)-17-hydro-7-dehydroandrographolide anti-inflammatory activity test
将实施例2所得的化合物作用于脂多糖(LPS)诱导的RAW264.7小鼠巨噬细胞,用Griess试剂显色法检测培养上清液中NO水平,以受试药物抑制NO释放的能力作为筛选指标,评价化合物的抗炎活性。The compound obtained in Example 2 was applied to lipopolysaccharide (LPS)-induced RAW264.7 mouse macrophages, and the level of NO in the culture supernatant was detected by the Griess reagent colorimetric method. The ability of the tested drug to inhibit the release of NO was used as Screen indicators to evaluate the anti-inflammatory activity of the compound.
1.药物溶液的配制1. Preparation of drug solution
将单体化合物用DMSO溶解配制成1.564、3.125、6.250、12.50、25.00μg/ml溶液。The monomer compound was dissolved in DMSO to prepare a solution of 1.564, 3.125, 6.250, 12.50, 25.00 μg/ml.
2.试验方法2. Test method
(1)单个小鼠巨噬细胞悬液用含10%的胎牛血清培养液配制而成,取对数期的小鼠巨噬细胞RAW264.7接种到96孔板中,每孔10
5细胞数,设置3个复孔。
(1) a single cell suspension of mouse macrophages with 10% fetal bovine serum containing culture medium formulated, taking the number of macrophage RAW264.7 mouse seeded into 96-well plates, 105 cells per well Count and set 3 multiple holes.
(2)经过24小时培养,每孔加入不同浓度的受试药物同时加入1ug/mL LPS。(2) After 24 hours of incubation, add different concentrations of test drug to each well and add 1ug/mL LPS at the same time.
(3)37℃培养24小时后,每孔加Griess溶液100ul继续培养5分钟,停止培养。(3) After 24 hours of incubation at 37°C, add 100ul Griess solution to each well and continue to incubate for 5 minutes, then stop the incubation.
(4)用酶联免疫检测仪测定570nm波长处的光密度(OD)值,并计算NO抑制率。(4) Measure the optical density (OD) value at 570nm wavelength with an enzyme-linked immunoassay, and calculate the NO inhibition rate.
3.实验结果3. Experimental results
10-(S)-17-氢-7-去氢穿心莲内酯化合物对RAW264.7细胞中的NO抑制作用IC50为 9.184μg/ml,具体参见图4。The inhibitory effect of 10-(S)-17-hydro-7-dehydroandrographolide compound on NO in RAW264.7 cells has an IC50 of 9.184 μg/ml, see Figure 4 for details.
结果表明10-(S)-17-氢-7-去氢穿心莲内酯化合物对脂多糖(LPS)诱导的小鼠巨噬细胞RAW264.7NO的生成有显著抑制作用,可作为一氧化氮抑制剂,表明本发明所述化合物具有明显的抗炎活性;因此可以用于制备新的抗炎活性药物;进一步的,可用于治疗肺炎,如新型冠状病毒肺炎(COVID-19)。The results show that 10-(S)-17-hydro-7-dehydroandrographolide compound has a significant inhibitory effect on the production of RAW264.7NO in mouse macrophages induced by lipopolysaccharide (LPS), and can be used as a nitric oxide inhibitor , Indicating that the compound of the present invention has obvious anti-inflammatory activity; therefore, it can be used to prepare new anti-inflammatory active drugs; further, it can be used to treat pneumonia, such as novel coronavirus pneumonia (COVID-19).
Claims (10)
- 一种新穿心莲内酯衍生物10-(S)-17-氢-7-去氢穿心莲内酯的制备方法,A new preparation method of andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide,其特征在于,包括以下步骤:It is characterized in that it includes the following steps:(1)大孔吸附树脂柱纯化:将穿心莲内酯总磺化物用水溶解,上样于大孔吸附树脂柱,采用有机溶剂和水混合溶剂进行洗脱,合并含有10-(S)-17-氢-7-去氢穿心莲内酯的洗脱液,浓缩,得粗品1;(1) Macroporous adsorption resin column purification: Dissolve andrographolide total sulfonate in water, load the sample on the macroporous adsorption resin column, use a mixed solvent of organic solvent and water for elution, and combine to contain 10-(S)-17- The eluent of hydrogen-7-dehydroandrographolide was concentrated to obtain crude product 1;(2)硅胶柱纯化:将粗品1用混合有机溶剂(A/B)溶解,上样于硅胶柱进行纯化,用混合有机溶剂(A/B)洗脱,用紫外在线检测器检测分离情况,根据出峰时间及色谱峰高度,确定洗脱液收集起止时间,收集洗脱液进行HPLC检测,根据检测结果合并含有10-(S)-17-氢-7-去氢穿心莲内酯的洗脱液,浓缩,得粗品2;(2) Silica gel column purification: dissolve the crude product 1 in a mixed organic solvent (A/B), load the sample on a silica gel column for purification, elution with a mixed organic solvent (A/B), and detect the separation with a UV on-line detector. According to the peak time and chromatographic peak height, determine the start and end time of eluent collection, collect the eluent for HPLC detection, and combine the elution containing 10-(S)-17-hydro-7-dehydroandrographolide according to the test results Liquid, concentrate, get crude product 2;(3)重结晶:将粗品2用有机溶剂溶解,挥发部分有机溶剂,析出固体,过滤,干燥。(3) Recrystallization: Dissolve the crude product 2 in an organic solvent, evaporate part of the organic solvent, and precipitate a solid, filter, and dry.
- 根据权利要求2所述的制备方法,其特征在于:所述步骤(1)中,大孔吸附树脂为苯乙烯型大孔吸附树脂,优选树脂型号HPD-100S、D101S或LX-1180。The preparation method according to claim 2, characterized in that: in the step (1), the macroporous adsorption resin is a styrene-type macroporous adsorption resin, preferably the resin model HPD-100S, D101S or LX-1180.
- 根据权利要求2所述的制备方法,其特征在于:所述步骤(1)中,有机溶剂为醇类溶剂;和/或,有机溶剂和水混合溶剂为体积比0%~60%甲醇-水溶液或体积比0%~60%乙醇-水溶液;和/或,浓缩温度为40~50℃。The preparation method according to claim 2, characterized in that: in the step (1), the organic solvent is an alcohol solvent; and/or the mixed solvent of the organic solvent and water is a methanol-water solution with a volume ratio of 0% to 60% Or, the volume ratio is 0%-60% ethanol-water solution; and/or, the concentration temperature is 40-50°C.
- 根据权利要求2所述的制备方法,其特征在于:所述步骤(2)中,The preparation method according to claim 2, characterized in that: in the step (2),混合有机溶剂(A/B)中A为石油醚或环己烷,B为乙酸乙酯、二氯甲烷、氯仿或丙酮;In the mixed organic solvent (A/B), A is petroleum ether or cyclohexane, and B is ethyl acetate, dichloromethane, chloroform or acetone;优选的,混合有机溶剂(A/B)为石油醚/丙酮溶液;Preferably, the mixed organic solvent (A/B) is a petroleum ether/acetone solution;更优选的,溶解时采用体积比5:1~4:1的石油醚/丙酮溶液;和/或,洗脱时采用溶剂为体积比5:1~1:1的石油醚/丙酮溶液。More preferably, a petroleum ether/acetone solution with a volume ratio of 5:1 to 4:1 is used for dissolving; and/or a petroleum ether/acetone solution with a solvent of 5:1 to 1:1 by volume is used for elution.
- 根据权利要求2所述的制备方法,其特征在于:所述步骤(2)中,HPLC色谱柱的填料为反相C18填料,优选为XAqua、ODS-A或ODS-AQ。The preparation method according to claim 2, characterized in that: in the step (2), the packing of the HPLC chromatographic column is a reversed-phase C18 packing, preferably XAqua, ODS-A or ODS-AQ.
- 根据权利要求2所述的制备方法,其特征在于:所述步骤(2)中,紫外在线检测器的检测波长为150~300nm;和/或,浓缩温度为40~50℃。The preparation method according to claim 2, characterized in that: in the step (2), the detection wavelength of the ultraviolet on-line detector is 150-300 nm; and/or the concentration temperature is 40-50°C.
- 根据权利要求2所述的制备方法,其特征在于:所述步骤(3)中,有机溶剂为乙酸乙酯;和/或,重结晶次数大于或等于2次;和/或,干燥方法为减压干燥。The preparation method according to claim 2, characterized in that: in the step (3), the organic solvent is ethyl acetate; and/or, the number of recrystallizations is greater than or equal to 2; and/or, the drying method is reduced Press dry.
- 一种以如权利要求1所述的如式(I)所示的新穿心莲内酯衍生物10-(S)-17-氢-7-去氢穿心莲内酯或权利要求2-8任一项所述方法制得的新穿心莲内酯衍生物10-(S)-17-氢-7-去氢穿心莲内酯作为药物活性成分的药物制剂,所述的药物制剂优选地包括但不限于注射剂、片剂、胶囊、分散片。A new andrographolide derivative represented by formula (I) as claimed in claim 1, 10-(S)-17-hydro-7-dehydroandrographolide or any one of claims 2-8 The new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide prepared by the method is used as a pharmaceutical preparation of the active ingredient of the medicine. The pharmaceutical preparation preferably includes, but is not limited to, injection, Tablets, capsules, dispersible tablets.
- 权利要求1所述的新穿心莲内酯衍生物10-(S)-17-氢-7-去氢穿心莲内酯或权利要求2-8任一项所述方法制得的新穿心莲内酯衍生物10-(S)-17-氢-7-去氢穿心莲内酯或权利要求9所述的药物制剂在制备治疗炎症疾病药物中的用途,所述炎症疾病优选肺炎,所述肺炎优选新型冠状病毒肺炎(COVID-19)。The new andrographolide derivative 10-(S)-17-hydro-7-dehydroandrographolide of claim 1 or the new andrographolide derivative prepared by the method of any one of claims 2-8 Use of 10-(S)-17-hydro-7-dehydroandrographolide or the pharmaceutical preparation of claim 9 in the preparation of a medicine for the treatment of inflammatory diseases, the inflammatory disease is preferably pneumonia, and the pneumonia is preferably a novel coronavirus Pneumonia (COVID-19).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010362402.1A CN113582951B (en) | 2020-04-30 | 2020-04-30 | 10- (S) -17-hydrogen-7-dehydroandrographolide and industrial chromatographic preparation method and application thereof |
CN202010362402.1 | 2020-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021218148A1 true WO2021218148A1 (en) | 2021-11-04 |
Family
ID=78237166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/132794 WO2021218148A1 (en) | 2020-04-30 | 2020-11-30 | 10-(s)-17-hydrogen-7-dehydro-andrographolidume, industrial chromatography-based preparation method therefor, and use thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113582951B (en) |
WO (1) | WO2021218148A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116354811A (en) * | 2023-02-22 | 2023-06-30 | 江中药业股份有限公司 | Labdane diterpenoid compound, preparation method and application |
CN117946059A (en) * | 2024-03-27 | 2024-04-30 | 江西中医药大学 | Monoterpene compound in herba Senecionis Scandentis of radish leaves, and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103145657A (en) * | 2012-04-12 | 2013-06-12 | 江西青峰药业有限公司 | 17-hydro-9-dehydroandrographolide compound and its preparation method and use in drug preparation |
WO2016065264A1 (en) * | 2014-10-24 | 2016-04-28 | Biogen Ma Inc. | Diterpenoid derivatives and methods of use thereof |
CN107973764A (en) * | 2016-10-24 | 2018-05-01 | 江西青峰药业有限公司 | Andrographolide class compound, its preparation method, pharmaceutical composition and application |
CN108392478A (en) * | 2017-02-07 | 2018-08-14 | 江西青峰药业有限公司 | Application of the andrographolide class compound in terms of preparing for radioactive damage drug |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108148022B (en) * | 2016-12-02 | 2023-04-18 | 江西青峰药业有限公司 | Andrographolide compound, pharmaceutical composition and application thereof |
-
2020
- 2020-04-30 CN CN202010362402.1A patent/CN113582951B/en active Active
- 2020-11-30 WO PCT/CN2020/132794 patent/WO2021218148A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103145657A (en) * | 2012-04-12 | 2013-06-12 | 江西青峰药业有限公司 | 17-hydro-9-dehydroandrographolide compound and its preparation method and use in drug preparation |
WO2016065264A1 (en) * | 2014-10-24 | 2016-04-28 | Biogen Ma Inc. | Diterpenoid derivatives and methods of use thereof |
CN107973764A (en) * | 2016-10-24 | 2018-05-01 | 江西青峰药业有限公司 | Andrographolide class compound, its preparation method, pharmaceutical composition and application |
CN108392478A (en) * | 2017-02-07 | 2018-08-14 | 江西青峰药业有限公司 | Application of the andrographolide class compound in terms of preparing for radioactive damage drug |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116354811A (en) * | 2023-02-22 | 2023-06-30 | 江中药业股份有限公司 | Labdane diterpenoid compound, preparation method and application |
CN116354811B (en) * | 2023-02-22 | 2024-02-27 | 江中药业股份有限公司 | Labdane diterpenoid compound, preparation method and application |
CN117946059A (en) * | 2024-03-27 | 2024-04-30 | 江西中医药大学 | Monoterpene compound in herba Senecionis Scandentis of radish leaves, and preparation method and application thereof |
CN117946059B (en) * | 2024-03-27 | 2024-06-04 | 江西中医药大学 | Monoterpene compound in herba Senecionis Scandentis of radish leaves, and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN113582951B (en) | 2024-03-19 |
CN113582951A (en) | 2021-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021218148A1 (en) | 10-(s)-17-hydrogen-7-dehydro-andrographolidume, industrial chromatography-based preparation method therefor, and use thereof | |
CN101969942A (en) | Therapeutic formulations based on asiatic acid and selected salts thereof | |
WO2022160455A1 (en) | Compound for preventing and treating inflammation, and preparation method therefor and use thereof | |
CN110746474A (en) | Dammarane type triterpenoid saponin compound, preparation method thereof and application thereof in preparation of anti-inflammatory drugs | |
AU2022352631A1 (en) | Azulene compound, and preparation method therefor and use thereof | |
CN111704544A (en) | Labdane diterpenoid compound and separation method and application thereof | |
CN103599145A (en) | Helleborus thibetanus extract, separation method of effective components in Helleborus thibetanus extract and compounds obtained by separation method | |
Wang et al. | Bioactivity-guided isolation of cyclooxygenase-2 inhibitors from Saussurea obvallata (DC.) Edgew. Using affinity solid phase extraction assay | |
CN111253247A (en) | Preparation method and application of novel phenolic acid compound with anti-inflammatory activity | |
CN109796511B (en) | Novel iridoid compound and preparation method and medical application thereof | |
CN115340512B (en) | Three diaryl butyrolactone lignans compounds in jellyfish herba Saussureae Involueratae, and extraction and separation method and application thereof | |
CN113620914B (en) | Andrographolide derivative and industrial chromatographic preparation method and application thereof | |
CN113512017B (en) | Compound in radish leaf groundsel and preparation method and application thereof | |
CN114933602A (en) | High-oxidation germacrane type sesquiterpene lactone compounds in elephantopus scaber and preparation method and application thereof | |
Song et al. | Elucidation for the pharmacological effects and mechanism of Shen Bai formula in treating myocardial injury based on energy metabolism and serum metabolomic approaches | |
CN116970017B (en) | Tetracyclic triterpene compound and preparation method and application thereof | |
CN116813681B (en) | 21, 24-cyclized lanolin alkane type triterpene compound and preparation method and application thereof | |
CN116162095B (en) | Hamatelin alkaloid and application thereof in preparation of anti-inflammatory drugs | |
CN115160114B (en) | Five aryl naphthalene type lignans compounds in jellyfish saussurea involucrata and extraction and separation method and application thereof | |
CN118373836B (en) | New compound extracted from small wampee, extraction method and application | |
CN117946059B (en) | Monoterpene compound in herba Senecionis Scandentis of radish leaves, and preparation method and application thereof | |
CN111518149B (en) | Alkaloid compound, preparation method and application | |
CN112538100B (en) | Isoquinoline alkaloid glycoside compound extracted from cortex Phellodendri and having anti-inflammatory activity, and its preparation method and application | |
CN113024494B (en) | Phenanthrene compound, preparation method and application | |
JP4792596B2 (en) | Ishizu orchid extract and its preparation method and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20933245 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20933245 Country of ref document: EP Kind code of ref document: A1 |